Preventing cervical cancer globally by acting locally: If not now, when?

Journal of the National Cancer Institute

Volumn 102, Issue 20, 2010, Pages 1524-1527

  Gage, Julia C ^a   Castle, Philip E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

CANCER GRADING; CANCER INVASION; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; COLPOSCOPY; CRYOTHERAPY; DEVELOPING COUNTRY; EARLY CANCER; EDITORIAL; FEMALE; HUMAN; PRECANCER; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS; ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; COMPLICATION; ECONOMICS; GENETICS; ISOLATION AND PURIFICATION; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOUTH AFRICA; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR; VIROLOGY;

ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CRYOTHERAPY; DNA, VIRAL; FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 77958601364     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq382     Document Type: Editorial

References (31)

1. Farley J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008: Cancer Incidence and Mortality Worldwide. Lyon, France: International Agency for Research on Cancer; 2010. IARC CaseBase 10.
2. FUTURE II Study Group. Quadrivalent vaccine against human papillo-mavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19): 1915-1927.
3. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928-1943. (Pubitemid 46740303)
4. Paavonen J, Naud P, Salmeron J, et al. Effcacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): fnal analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301-314.
5. Denny L, Kuhn L, Hu C-C, Tsai W-Y, Wright TC Jr. Human papillomavi-rus-based cervical cancer prevention: long-term results of a randomized screening trial. J Natl Cancer Inst. 2010;102(20):1557-1567.
6. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119(5):1095-1101.
7. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papilloma-virus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357(16):1579-1588.
8. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007; 357(16):1589-1597.
9. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370(9601):1764-1772.
10. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337:a1754. doi:10.1136/bmj.a1754.
11. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009;360(14):1385-1394.
12. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Effcacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11(3):249-257.
13. Anttila A, Kotaniemi-Talonen L, Leinonen M, et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ. 2010;340:c1804. doi:10.1136/bmj.c1804.
14. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003;95(1):46-52.
15. Schiffman M, Castle PE. The promise of global cervical-cancer prevention. N Engl J Med. 2005;353(20):2101-2104.
16. Qiao YL, Sellors JW, Eder PS, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol. 2008;9(10):929-936.
17. Averbach SH, Gravitt PE, Nowak RG, et al. The association between cervical human papillomavirus infection and HIV acquisition among women in Zimbabwe. AIDS. 2010;24(7):1035-1042.
18. Smith JS, Moses S, Hudgens MG, et al. Increased risk of HIV acquisition among Kenyan men with human papillomavirus infection. J Infect Dis. 2010;201(11):1677-1685.
19. Smith-McCune KK, Shiboski S, Chirenje MZ, et al. Type-specifc cervico-vaginal human papillomavirus infection increases risk of HIV acquisition independent of other sexually transmitted infections. PLoS One. 2010;5(4):e10094.
20. Veldhuijzen NJ, Vyankandondera J, van de Wijgert JH. HIV acquisition is associated with prior high-risk human papillomavirus infection among high-risk women in Rwanda. AIDS. 2010;24(14):2289-2292.
21. Gage JC, Rodriguez AC, Schiffman M, et al. An evaluation by midwives and gynecologists of treatability of cervical lesions by cryotherapy among human papillomavirus-positive women. Int J Gynecol Cancer. 2009;19(4): 728-733.
22. Castle PE, Stoler MH, Solomon D, Schiffman M. The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. Am J Clin Pathol. 2007;127(5):805-815.
23. Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol. 2009;113(1):18-25.
24. Trimble CL, Piantadosi S, Gravitt P, et al. Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res. 2005;11(13):4717-4723.
25. Castle PE, Schiffman M, Herrero R, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in guanacaste, costa rica. J Infect Dis. 2005;191(11):1808-1816.
26. Pretorius RG, Belinson JL. Letter to the editor concerning Petignat et al.'s "Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis." Gynecol Oncol. 2007;105(2):530-535.
27. Gynecol Oncol. 2007;107(3):595-596.
28. Murillo R, Almonte M, Pereira A, et al. Cervical cancer screening programs in Latin America and the Caribbean. Vaccine. 2008;26(suppl 11): L37-L48.
29. Jeronimo J, Schiffman M. Colposcopy at a crossroads. Am J Obstet Gynecol. 2006;195(2):349-353.
30. Galgano MT, Castle PE, Atkins KA, Brix WK, Nassau SR, Stoler MH. Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am J Surg Pathol. 2010;34(8):1077-1087.
31. Kuhn L, Wang C, Tsai WY, Wright TC, Denny L. Effcacy of human papillomavirus-based screen-and-treat for cervical cancer prevention among HIV-infected women [published online ahead of print August 11, 2010]. AIDS. 2010.